471 DISTINGUISHING FEATURES OF ERG ONCOPROTEIN EXPRESSION AMONG MATCHED COHORTS OF AFRICAN-AMERICAN AND CAUCASIAN-AMERICAN PROSTATE CANCER PATIENTS

Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research III1 Apr 2012471 DISTINGUISHING FEATURES OF ERG ONCOPROTEIN EXPRESSION AMONG MATCHED COHORTS OF AFRICAN-AMERICAN AND CAUCASIAN-AMERICAN PROSTATE CANCER PATIENTS Philip Rosen, David Pfister, Denise Young, Gyorgy Petrovics, Yongmei Chen, Albert Dobi, David McLeod, Shiv Srivastava, and Isabell Sesterhenn Philip RosenPhilip Rosen Bethesda, MD More articles by this author , David PfisterDavid Pfister Aachen, Germany More articles by this author , Denise YoungDenise Young Rockville, MD More articles by this author , Gyorgy PetrovicsGyorgy Petrovics Rockville, MD More articles by this author , Yongmei ChenYongmei Chen Rockville, MD More articles by this author , Albert DobiAlbert Dobi Rockville, MD More articles by this author , David McLeodDavid McLeod Bethesda, MD More articles by this author , Shiv SrivastavaShiv Srivastava Rockville, MD More articles by this author , and Isabell SesterhennIsabell Sesterhenn Silver Spring, MD More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.540AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The ETS-related gene (ERG) proto-oncogene is frequently overexpressed in Prostate Cancer (CaP) as a result of a genomic rearrangement that places ERG under the control of the androgen-dependent TMPRSS2 promoter. The initial report of quantitative ERG mRNA expression in micro-dissected prostate tumor cells showed significantly higher ERG expression in CaP of Caucasian-Americans (CA) patients vs. African-American (AA) patients (Petrovics et al, Oncogene, 2005). Recent studies (Magi-Galluzzi et al, Prostate, 2011; Elliott et al, USCAP Mtg., 2011) have also shown higher frequency of ERG rearrangement or ERG oncoprotein expression in CaP of CA patients. We evaluate the frequency and pattern of the ERG oncoprotein expression in prostate tumors of matched CA and AA CaP patients to better understand the biological basis for differences in prostate cancer between the two populations. METHODS Ninety one AA and 91 CA CaP patients were matched for age, Gleason score and pathologic stage. All underwent radical prostatectomy between 1993 and 2010. Whole mount prostate specimens were used for the immunohistochemical detection of the ERG oncoprotein by a highly specific ERG monoclonal antibody (clone 9FY). Individual foci of tumors were reported as either positive or negative. Biochemical recurrence (BR) was defined as two serum PSA measurements of ≥0.2 ng/mL at least 8 weeks from surgery. RESULTS A higher percentage of CA (61.8%) than AA (28.2%) CaP patients had ERG (+) index tumors and had at least one focus of tumor positive for ERG. A higher percentage of overall tumor foci from CA than AA CaP patients was ERG (+) (table 1). There was a slight trend towards increased BR in CA CaP patients with ERG (+) index tumors. There was high concordance of ERG expression between CaP and adjacent prostatic intra-epithelial neoplasia (PIN) in both AA and CA patients. Table 1. Association of ERG IHC status with race/ethnicity ERG IHC Overall Caucasian-American African-American p value Number of patients 182 91 91 Patients with ERG (+) index tumor 79(45.4) 55(61.8) 24(28.2) <0.0001 Patients with at least 1 focus of ERG (+) tumor 100(55.0) 59(64.8) 41(45.0) 0.0073 Number of tumor foci 379 183 196 ERG (+) foci 128(33.8) 77(42.1) 51(26.0) 0.001 CONCLUSIONS ERG expression is more prevalent among CA than AA CaP patients in matched cohorts. Differences in the pattern of ERG expression in CaP and differing trends in BR between CA and AA patients with ERG (+) index tumors suggest a dominant clonal selection of ERG-positive tumors in CA patients. These differences in ERG expression have the potential to delineate biological distinctions of CaP in the two patient populations. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e193 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Philip Rosen Bethesda, MD More articles by this author David Pfister Aachen, Germany More articles by this author Denise Young Rockville, MD More articles by this author Gyorgy Petrovics Rockville, MD More articles by this author Yongmei Chen Rockville, MD More articles by this author Albert Dobi Rockville, MD More articles by this author David McLeod Bethesda, MD More articles by this author Shiv Srivastava Rockville, MD More articles by this author Isabell Sesterhenn Silver Spring, MD More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...